EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

1. Which GLP-1 procurement route should a clinic evaluate first?

Dose Diligence research deskSection 01 · Page 1 of 34Last updated 17 Nov 2026

Evaluate approved-medicine access first, then determine whether the clinic should own inventory or simply coordinate dispensing. Keep any proposed compounded preparation in a separate, product-specific clinical and legal review. FDA recommends approved medicines when they can meet the patient’s needs; compounded medicines do not undergo the same premarket review. (fda.gov)

Use this proposed route map:

RouteWhat the clinic should establishMain commercial question
Approved medicine purchased as clinic inventoryPurchasing eligibility, permitted handling and intended administration or dispensingWhat acquisition cost and inventory exposure does the clinic actually bear?
Approved medicine dispensed by a pharmacyProduct acceptance, patient coverage, destination permissions and workflowWhat service performance can the clinic obtain without owning medicine?
Manufacturer-linked patient accessExact programme, presentation, eligibility and prescribing destinationIs the patient journey workable at ongoing—not introductory—prices?
Proposed compounded preparationApplicable pathway, ingredients, prescribing rationale, facility and destination requirementsShould this arrangement proceed to commercial evaluation at all?

LillyDirect and NovoCare describe prescription-to-patient access arrangements; those descriptions do not establish a clinic’s wholesale purchasing entitlement. (lilly.com)

First deliverable: a one-page diagram showing who prescribes, compounds if applicable, dispenses, ships, invoices, owns inventory and handles complaints. Do not accept a proposal that leaves these entities unnamed.

Explore the table row by row

A working view of the research

Approved medicine purchased as clinic inventory

What the clinic should establish
Purchasing eligibility, permitted handling and intended administration or dispensing
Main commercial question
What acquisition cost and inventory exposure does the clinic actually bear?

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers?trk=article-ssr-frontend-pulse_little-text-block&utm_source=openai
  2. lilly.com · Source 2 ↗https://www.lilly.com/lillydirect/faq
Section sources →